Opening Bell
JPMorgan Chase kicked off major bank earnings with a strong Q1 beat, reporting EPS of $5.94 against LSEG estimates of $5.45 and revenue of $50.54 billion topping $49.17 billion expected, driven by robust fixed income trading and investment banking fees amid heightened market volatility from the Iran conflict. The results underscore Wall Street's resilience, with markets divisions capitalizing on oil price swings and geopolitical uncertainty that boosted trading volumes, even as consumer-facing segments face pressure from energy cost shocks acting as a regressive tax.
CEO Jamie Dimon's commentary will be scrutinized for stagflation signals, with full-year net interest income guidance at $103-104.5 billion a key watchpoint; analysts note the beat aligns with pre-earnings optimism for 7-8% revenue growth, though credit provisions rose to $2.507 billion amid economic headwinds. Observers on X highlighted the print's quality, positioning JPM as a sector bellwether ahead of peers like Citigroup and Wells Fargo, potentially restoring confidence in banks after a weak quarterly start.
Goldman Sachs delivered its second-highest quarterly revenue ever at $17.23 billion, up 14% year-over-year, with EPS of $17.55 crushing estimates of $16.47, propelled by a record $5.33 billion in equities trading revenue that shattered prior highs by over $1 billion. Investment banking fees climbed on resurgent dealmaking, while fixed income lagged at $4.01 billion versus expectations, reflecting broader volatility from the Iran war that favored equity desks but pressured other areas; ROE hit 19.8% with $5 billion in buybacks supporting capital returns.
Despite the breadth of the beat—including strong wealth management inflows of $62 billion—the stock dipped over 3% post-earnings, as investors parsed doubled credit loss provisions to $315 million, the largest jump since 2020, signaling caution on consumer credit amid inflation and energy squeezes. Analysts like those at WSJ view it as confirmation of Wall Street's trading engine revving amid chaos, setting a high bar for the sector with Goldman's S&P 500 target at 7,600.
The International Energy Agency slashed its 2026 global oil demand forecast to a contraction—the first decline since the 2020 pandemic—wiping out prior growth projections as war-driven supply disruptions and prices topping $100/barrel crush consumption of crude, jet fuel, diesel, and gasoline. Strait of Hormuz flows plummeted from over 20 million bpd pre-war to 3.8 million bpd in early April, representing the largest supply disruption in oil market history at 7.5% of global volumes, with demand destruction accelerating by over 1 million bpd in March-April alone.
IEA advisers warn scarcity and persistent high costs will spread pain economy-wide, complicating OPEC+ responses and central bank outlooks; market observers note China's exploitation of non-Iranian port carve-outs has softened some physical tightness, but Brent's $100 floor holds amid no reopening timeline for Hormuz.
U.S. consumer prices surged 0.9% in March—the largest monthly jump since 2022—with annual inflation hitting 3.3% as Iran war spikes sent energy costs up nearly 11%, eroding paychecks and fueling uniform concern across demographics on price pressures. University of Michigan's sentiment index plunged 11% to a record low of 47.6 in early April, reflecting frustration with gas prices and broader economic toll, now surpassing WWII-era lows in some metrics.
The energy shock has acted like a regressive tax, with real wages flatlining as gasoline eats into disposable income; Fed officials still eye a 2026 rate cut despite the flare-up, but brokerages stick to two cuts mid-year amid stagflation risks hardening from oil volatility.
Johnson & Johnson posted Q1 sales of $24.1 billion, up 9.9% reported, with adjusted EPS of $2.70, prompting an upbeat full-year raise to $100.8 billion in sales (7% growth) and adjusted EPS of $11.55 (7.1% growth), signaling strength in pharmaceuticals and medtech amid economic turbulence. The performance beat consensus whispers for EPS around $2.68 and revenue near $23.6 billion, driven by key drug momentum and operational resilience despite inflation headwinds.
Analysts view the guidance hike as validation of steady growth into 2026-2027, with stable EPS estimates reflecting confidence in pipeline advancements; the stock held flat pre-earnings, outperforming a choppy market as healthcare proves defensive in war-disrupted volatility.